During an unprecedented year, Rentschler Biopharma continued to meet the demands of its core protein therapeutic business while expanding into novel therapeutics. The CDMO continues to expand and innovate beyond the pandemic by pioneering digitized processes and adding capabilities in response to client needs. The company offers services along the entire biopharmaceutical value chain — via both in-house expertise and an array of best-in-class strategic alliance partners. Senior Vice President for Business Development Federico Pollano explains how the company is leveraging its 50-year experience and dual sites in Germany and the United States to flexibly meet market demand.
Read why quality, flexibility and trust are key for us to maintain a close relationship with clients worldwide. The industry recognizes this dedication, which is why we are considered best-in-class in service quality, as well as regulatory affairs — including regulatory support, CMC consulting, and outlining the product path from concept to registration.